CoChat

Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia

Open access
Machado-Duque, Manuel Enrique, Gaviria-Mendoza, Andrés, Valladales-Restrepo, Luis Fernando, Machado-Alba, Jorge Enrique · 2025 · Drugs - Real World Outcomes

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Semaglutide is an effective antidiabetic agent that is injected weekly to induce weight reduction, and the impact on cardiovascular outcomes is favorable. OBJECTIVE: The aim was to evaluate the persistence of the use of weekly injectable semaglutide in Colombia for 12 months among new users. METHODS: A retrospective longitudinal follow-up study of a cohort of patients with a new prescription of weekly injectable semaglutide between January and December 2022 and persistence for 365 days was evaluated. Kaplan‒Meier survival analyses were performed to evaluate the survival effect of semaglutide. RESULTS: In total, 9356 new users of semaglutide were identified. The average age of the users was 61.6 ± 12.9 years, the main diagnoses were type 2 diabetes mellitus (43.8%) and obesity (41.8%), and 90.8% of them received the 0.25/0.5-mg dose. The mean duration of use was 93.7 ± 76.3 days, but only 13.8% and 0.2% of patients continued the treatment at 6 and 12 months of follow-up, respectively. In total, 35.4% had a prescription for a single month. The other concomitant antidiabetic drugs used were metformin (43.5%), sodium glucose-2 cotransporter inhibitors (38.3%) and insulin (18.2%). CONCLUSIONS: Most of the patients started semaglutide at the suggested doses to continue with staging; however, the persistence of use was low, which may be related to difficulties in access, education on application methods, drug tolerability, and lack of follow-up by the clinician.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40801-025-00518-6

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Survival analysis in the persistence of semaglutide use in new users, Colombia 2022
Fig. 1 Survival analysis in the persistence of semaglutide use in new users, Colombia 2022CC BY-NC · PubMed Central
Fig. 2 Survival analysis in the persistence of use of semaglutide between the presentation of 0.25/0.5mg vs 1 mg per dose in new users, Colombia 2022
Fig. 2 Survival analysis in the persistence of use of semaglutide between the presentation of 0.25/0.5mg vs 1 mg per dose in new users, Colombia 2022CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Metadata

Authors
Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E.
Venue
Drugs - Real World Outcomes
Published
2025-10-03
Volume
12
Issue
4
Pages
615-622
ISSN
  • 2198-9788 (ISSN-L)
  • 2199-1154
OpenAlex
W4414773967
Cited by
2
References
25
Citations by year
2026: 2
FWCI
1.36
Type
journal article
Language
en
Open access
Licence
Locations
  • Drugs - Real World Outcomes (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, treatment persistence, type 2 diabetes, obesity, GLP-1 receptor agonists, weight loss, antidiabetic drugs, metformin, SGLT2 inhibitors, insulin, drug tolerability, access to medicines, Colombia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.